Supplementary File 1

Association between the baseline plasma EV synaptic proteins with the clinical severity in people with Parkinson’s disease at follow-up with the adjustment of age, sex, disease duration and the baseline severity of corresponding item, presented as standardized B and p value.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | UPDRSII | UPDRSIII |  |  |  | MMSE | MoCA |
|  |  |  | Tremor | AR | PIGD |  |  |
| SNAP-25 | 0.137 (0.132) | 0.126 (0.135) | -0.032 (0.753) | 0.090 (0.278) | **0.216 (0.004)** | -0.069 (0.400) | 0.014 (0.811) |
| GAP-43 | 0.127 (0.162) | 0.111 (0.186) | -0.034 (0.737) | 0.084 (0.312) | **0.166(0.030)** | -0.041 (0.617) | -0.010 (0.862) |
| Synaptomagtin-1 | 0.108 (0.223) | 0.064 (0.41) | -0.055 (0.582) | 0.042 (0.609) | 0.139 (0.06) | -0.009 (0.911) | -0.002 (0.967) |

UPDRS, unified Parkinson Disease rating scale; AR, akinetic rigidity; PIGD, postural instability and gait disturbance; MMSE, mini-mental status examination; MoCA, Montreal cognitive assessment.